Clicky

BioLineRx Ltd.(BLRX) News

Date Title
Jun 10 BLRX: First Quarter 2024 Results
May 6 BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
Apr 17 BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Apr 10 BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Apr 1 BioLineRx Announces $6 Million Registered Direct Offering
Mar 27 BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
Mar 27 BLRX: First Aphexda Sales Recognized
Mar 26 BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Mar 20 BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
Mar 4 BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Feb 16 BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Dec 21 BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
Nov 20 BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Nov 2 3 Tech Stocks That Wall Street Loves More Than Nvidia
Sep 11 BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
Sep 5 BLRX: On Your Marks, Get Set…
May 24 BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates